Loading…
← CockpitCompetitor Analysis › 2675.HK Shenzhen Edge Medical Co., Ltd. Class HOpen in the cockpit ↗

Shenzhen Edge Medical Co., Ltd. Class H2675.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Medical Specialties

Chinese maker of surgical robotic systems for minimally invasive laparoscopic and endoscopic surgery.

≈ China's answer to a smaller Intuitive SurgicalMomentum laggard 13
Mkt cap
$1.21B
US dollars, full cap
Free float
33%
of shares outstanding
$/day
$1.41M
20-day average traded
Fwd P/E
120.2×
forward earnings
ROIC−WACC
-6.2 pp
WACC 8.2%
Hurdle
n/a
no reverse DCF
Next earnings
131 days
29 Mar 2027
Close · HKDHK$24.60
1D-3.1%
1W-13.7%
1M-23.1%
3M-32.0%
6M-50.9%
YTDn/a
1Yn/a
ATR %6.6%
52w lowhigh66.6% off high

What Shenzhen Edge Medical does

Chinese maker of surgical robotic systems for minimally invasive laparoscopic and endoscopic surgery.

In one line: China's answer to a smaller Intuitive Surgical.

Products and services

  • Laparoscopic surgical robot systems
  • Surgical instruments/consumables

Customers

  • Hospitals performing minimally invasive surgery in

Where it sits in the supply chain

  • Health Care
  • Medical devices
  • Surgical robotics

What could go right

  • China minimally invasive surgery adoption growth

What could go wrong

  • Long hospital sales/adoption cycles
  • Competition from established robotic-surgery leaders

Moat: narrow (IP / patents, regulatory licence, switching costs). Regulatory approvals and surgeon training/installed base create switching costs once a hospital adopts a robotic platform.

Headquarters: Shenzhen, China · Employees: 602

Named competitors

Shenzhen Edge Medical at a glance

Size Shenzhen Edge Medical (2675.HK) is a Hong Kong Health Care company (Medical Specialties) with a market value of $1.21B, the 530th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$24.60 on 18 Nov 2026.

Performance Over six months the shares fell 50.9%, against -9.9% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 2nd lowest of 20 in its peer set.

Growth Revenue grew 132.2% over the last twelve months (peer median +12.0%); the operating margin is 2.0% (peer median 16.0%).

Valuation It trades at 120.2× forward earnings against a peer median of 28.2× (most expensive of 15).

Capital Return on invested capital runs 6.2 points below its cost of capital (8.2% WACC).

Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).

Relative performance

507510021 May 202621 Aug 202618 Nov 2026Peer median 882675.HK 49
Six months, rebased to 100: Shenzhen Edge Medical against the median of its 20 peers (local-currency closes).

Shenzhen Edge Medical financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2021
RevenueHK$699MHK$494MHK$173MHK$53.1MHK$0
Revenue growth—+185%+227%——
Gross profitHK$457MHK$318MHK$93.7MHK$18.2M-HK$8.00M
EBITDAHK$37.0M-HK$61.3M-HK$282M-HK$277M-HK$327M
Net income-HK$21.4M-HK$96.1M-HK$237M-HK$235M-HK$290M
Free cash flow-HK$244M-HK$213M-HK$270M-HK$420M-HK$142M
Capital expenditureHK$16.6MHK$3.88MHK$29.3MHK$70.3MHK$9.01M
Total debtn/aHK$11.0MHK$19.2MHK$29.4MHK$18.2M

Quarterly statements and history in the cockpit →

Shenzhen Edge Medical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%688050TNDM688289NVCRSTAA688161300406688758688198DRTS300595ATEC214150301101688622SIBNIRMD2675.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Shenzhen Edge Medical is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×50×100×688050688289STAA688161300406300633688758688198300595ATEC214150IART2675.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shenzhen Edge Medical is the large dot.

Shenzhen Edge Medical competitors and peer comparison

Head to head with its named competitors (2675.HK vs ISRG vs 2252.HK vs MDT)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Shenzhen Edge Medical 2675.HK$1.21B-51%+132%2%120.2×n/a
Intuitive Surgical ISRG$146B-6%+20%32%34.8×29.6%
Shanghai MicroPort MedBot (Group) 2252.HKn/a-26%n/an/an/an/a
Medtronic MDT$129B+30%+10%20%16.8×9.1%

How Shenzhen Edge Medical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shenzhen Edge Medical against its 20 peers (data as of 18 Nov 2026)
Measure2675.HKPeer medianRank in peer set
1-month return-23.1%-5.8%5th lowest of 21
6-month return-50.9%-9.9%2nd lowest of 20
Distance from 52-week high-66.6%-37.5%3rd lowest of 21
Revenue growth (TTM)+132.2%+12.0%highest of 19
Operating margin2.0%16.0%7th lowest of 20
Forward P/E120.2×28.2×most expensive of 15
ROIC minus cost of capital-6.2 pp+0.2 pp6th lowest of 20
Net debt / EBITDA-56.7×-1.0×least indebted of 7

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Shenzhen Edge Medical 2675.HKHong Kong$1.21B-51%+132%2%120.2×n/an/a
Eyebright Medical Technology (Beijing) 688050.SSChina$1.21B-16%+21%16%23.9×10.3%+40.3%
Tandem Diabetes Care TNDMUnited States$1.19B+13%+7%-2%n/an/an/a
Sansure Biotech 688289.SSChina$1.24B-17%-1%1%35.6×n/an/a
NovoCure NVCRUnited States$1.25B-40%+13%-17%n/an/an/a
STAAR Surgical STAAUnited States$1.27B-23%+42%7%46.9×35.1%+7.9%
Shandong Weigao Orthopaedic Device 688161.SSChina$1.14B-29%-6%18%24.9×11.3%-3.5%
Beijing Strong Biotechnologies 300406.SZChina$1.13B-4%-4%36%18.2×1.7%+9.9%
Sonoscape Medical 300633.SZChina$1.31B-10%+18%4%34.7×n/an/a
Suzhou Sepax Technologies 688758.SSChina$1.31B+8%+28%40%46.0×22.8%+23.6%
Beijing Balance Medical Technology 688198.SSChina$1.31B-32%+10%28%41.5×20.7%+27.6%
Alpha Tau Medical DRTSUnited States$1.11B+7%n/an/an/an/an/a
Ovctek China 300595.SZChina$1.33B-25%0%28%19.4×8.3%+16.5%
Alphatec ATECUnited States$1.10B-14%+15%-3%15.1×n/an/a
Freenome FRNMUnited States$1.08Bn/an/a36%n/an/an/a
CLASSYS 214150.KSSouth Korea$1.08B-60%+16%43%13.7×-9.2%+34.5%
Integra LifeSciences IARTUnited States$1.08B-10%+1%12%6.0×5.9%+3.6%
Mingyue Optical Lens 301101.SZChina$1.07B-4%+14%25%31.6×8.8%+8.8%
Guangzhou Hexin Instrument 688622.SSChina$1.06B+21%-29%-74%n/an/an/a
SI-BONE SIBNUnited States$1.06B+59%+14%-8%n/an/an/a
IRadimed IRMDUnited States$1.05B-9%+11%32%34.3×18.5%+21.5%

Questions

Who are Shenzhen Edge Medical's main competitors?
Named competitors: Intuitive Surgical (ISRG), MicroPort MedBot (2252.HK), Medtronic (MDT). The cockpit's measured peer set (industry) also includes Eyebright Medical Technology (Beijing) (688050.SS), Tandem Diabetes Care (TNDM), Sansure Biotech (688289.SS), NovoCure (NVCR), STAAR Surgical (STAA), Shandong Weigao Orthopaedic Device (688161.SS).
Is Shenzhen Edge Medical expensive compared with its peers?
On forward p/e it trades at 120.2× against a peer median of 28.2×, most expensive of 15 in its peer set.
How has Shenzhen Edge Medical stock performed?
Over six months to 18 Nov 2026 the shares returned -50.9% against -9.9% for the median peer.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.